Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.72 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.66 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011003 | 1.00 | NR1H2 (0.72) | NR1H2ESR2ABHD6HDAC1MAPK1 | |
| Hydrochloric Acid SCHEMBL38653092 | 0.99 | NR1H2 (0.70) | NR1H2ESR2ABHD6HDAC1MAPK1 | |
| SCHEMBL587847 | 0.95 | ESR2 (0.74) | NR1H2ESR2ABHD6HDAC1MAPK1 | |
| SCHEMBL29528794 | 0.95 | ESR2 (0.74) | NR1H2ESR2ABHD6HDAC1MAPK1 | |
| SCHEMBL24265586 | 0.92 | NR1H2 (0.62) | NR1H2ESR2ABHD6HDAC1MAPK1 | |
| SCHEMBL29574152 | 0.92 | NR1H2 (0.62) | NR1H2ESR2ABHD6HDAC1MAPK1 | |
| SCHEMBL1263942 | 0.92 | ESR2 (0.61) | NR1H2ESR2ABHD6HDAC1NPC1 | |
| SCHEMBL30951607 | 0.89 | ABHD6 (0.60) | NR1H2ESR2ABHD6HDAC1MAPK1 | |
| SCHEMBL330056 | 0.89 | ABHD6 (0.60) | NR1H2ESR2ABHD6HDAC1MAPK1 | |
| SCHEMBL30199596 | 0.88 | NR1H2 (0.63) | NR1H2ESR2ABHD6HDAC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| EP-4676476-A1 | INHIBITORS OF TDP-43 AND TAU AGGREGATION | Aquinnah Pharmaceuticals, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| CN-120077042-A | 3A,4,5, 6-tetrahydro-1H-pyrazolo [3,4-C ] pyridin-7 (7 AH) -one derivatives as factor XIIa inhibitors | 卡尔维斯塔制药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-111819175-B | Broad-spectrum antiviral compositions and methods | 艾弗里斯生物有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4508061-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | Mabsoft Therapeutics (Shanghai) Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-119365479-A | Conjugates comprising Toll-like receptor agonists | 慕宝盛科生物医药(上海)有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119343339-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-116249554-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4157463-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
| CN-115594669-A | Fused ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-20230002413-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022235715-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| CN-115297861-A | Compound and use thereof | 福宏治疗公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-110511209-B | Indole carboxamide compounds useful as kinase inhibitors | 百时美施贵宝公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-109863145-B | Novel tetrahydroisoquinoline and tetrahydronaphthyridine compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | NR1H2 1619/4885ESR2 2561/4885ABHD6 4137/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | NR1H2 21/4885ESR2 3/4885ABHD6 2882/4885 |
| US-20230002413-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | NR1H2 372/4885ESR2 4285/4885ABHD6 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.